Inhibition of ATG4B enhanced PRMT1‐mediated DNA damage responses, suppressed cell proliferation, reduced the mutation burden, and prolonged survival in mice with MLLT3‐KMT2A‐induced AML and in those bearing AML patient‐derived xenografts. The gene discussed is PRMT1; the disease is acute myeloid leukemia.